Literature DB >> 9458277

Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner.

M E Brousseau1, S Santamarina-Fojo, B L Vaisman, D Applebaum-Bowden, A M Bérard, G D Talley, H B Brewer, J M Hoeg.   

Abstract

Lecithin:cholesterol acyltransferase (LCAT) is an enzyme well known for its involvement in the intravascular metabolism of high density lipoproteins; however, its role in the regulation of apolipoprotein (apo) B-containing lipoproteins remains elusive. The present study was designed to investigate the metabolic mechanisms responsible for the differential lipoprotein response observed between cholesterol-fed hLCAT transgenic and control rabbits. 131I-labeled HDL apoA-I and 125I-labeled LDL kinetics were assessed in age- and sex-matched groups of rabbits with high (HE), low (LE), or no hLCAT expression after 6 weeks on a 0.3% cholesterol diet. In HE, the mean total cholesterol concentration on this diet, mg/dl (230 +/- 50), was not significantly different from that of either LE (313 +/- 46) or controls (332 +/- 52) due to the elevated level of HDL-C observed in HE (127 +/- 19), as compared with both LE (100 +/- 33) and controls (31 +/- 4). In contrast, the mean nonHDL-C concentration for HE (103 +/- 33) was much lower than that for either LE (213 +/- 39) or controls (301 +/- 55). FPLC analysis of plasma confirmed that HDL was the predominant lipoprotein class in HE on the cholesterol diet, whereas cholesteryl ester-rich, apoB-containing lipoproteins characterized the plasma of LE and, most notably, of controls. In vivo kinetic experiments demonstrated that the differences in HDL levels noted between the three groups were attributable to distinctive rates of apoA-I catabolism, with the mean fractional catabolic rate (FCR, d-1) of apoA-I slowest in HE (0.282 +/- 0.03), followed by LE (0.340 +/- 0.01) and controls (0.496 +/- 0.04). A similar, but opposite, pattern was observed for nonHDL-C levels and LDL metabolism (h-1), such that HE had the lowest nonHDL-C levels with the fastest rate of clearance (0.131 +/- 0.027), followed by LE (0.057 +/- 0.009) and controls (0.031 +/- 0.001). Strong correlations were noted between LCAT activity and both apoA-I (r= -0.868, P < 0.01) and LDL (r = 0.670, P = 0.06) FCR, indicating that LCAT activity played a major role in the mediation of lipoprotein metabolism. In summary, these data are the first to show that LCAT overexpression can regulate both LDL and HDL metabolism in cholesterol-fed rabbits and provide a potential explanation for the prevention of diet-induced atherosclerosis observed in our previous study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9458277

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

Review 1.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

2.  Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo.

Authors:  Hiroyuki Tanigawa; Jeffrey T Billheimer; Jun-ichiro Tohyama; Ilia V Fuki; Dominic S Ng; George H Rothblat; Daniel J Rader
Journal:  Circulation       Date:  2009-06-29       Impact factor: 29.690

3.  LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency.

Authors:  Boris L Vaisman; Edward B Neufeld; Lita A Freeman; Scott M Gordon; Maureen L Sampson; Milton Pryor; Emily Hillman; Milton J Axley; Sotirios K Karathanasis; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2018-12-18       Impact factor: 4.030

Review 4.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

5.  AAV8-mediated long-term expression of human LCAT significantly improves lipid profiles in hCETP;Ldlr(+/-) mice.

Authors:  Zhu Chen; Donald Chu; Jose M Castro-Perez; Weihua Ni; Aiwu Zhang; Mihajlo L Krsmanovic; Dan Xie; Vinit Shah; Steven J Stout; David G McLaren; Alice C Stefanni; Sang Ho Lee; Thomas P Roddy; Andrew S Plump; Brian K Hubbard; Thomas F Vogt; Heather H Zhou
Journal:  J Cardiovasc Transl Res       Date:  2011-08-06       Impact factor: 4.132

6.  Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.

Authors:  Shen Qu; German Perdomo; Dongming Su; Fiona M D'Souza; Neil S Shachter; H Henry Dong
Journal:  J Lipid Res       Date:  2007-04-16       Impact factor: 5.922

Review 7.  Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

Authors:  Xavier Rousset; Robert Shamburek; Boris Vaisman; Marcelo Amar; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

8.  Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script.

Authors:  Daniel J Rader
Journal:  Circulation       Date:  2009-08-03       Impact factor: 29.690

Review 9.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

Review 10.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Authors:  Xavier Rousset; Boris Vaisman; Marcelo Amar; Amar A Sethi; Alan T Remaley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.